Efgartigimod alfa is in clinical development for the treatment of pemphigus vulgaris (PV) and pemphigus foliaceus (PF). Pemphigus is a rare long-term (chronic) condition caused by a problem with the immune system. For reasons not fully understood, antibodies (proteins developed by the body to fight infection) develop in the blood and mistakenly react with surface layers of the body causing painful blisters in the mouth (and other mucous membranes) and on the skin. PF is a rare relatively benign form of pemphigus that produces blisters confined to the skin, and unlike PV does not involve mucous membranes. Pemphigus can be life-threatening without treatment. Treatment is normally with corticosteroids but when taken for long periods corticosteroids can cause a range of side effects.
Efgartigimod alfa for treating pemphigus vulgaris or pemphigus foliaceus
Efgartigimod alfa is in clinical development for the treatment of pemphigus vulgaris (PV) and pemphigus foliaceus (PF). Pemphigus is a rare long-term (chronic) condition caused by a problem with the immune system.